经皮给药系统治疗乳腺癌的研究进展  

Advances in Transdermal Drug Delivery System for Treating Breast Cancer

作　　者：王雪娇 赵锋 马银玲 吴献[1] 曹德英 WANG Xue-jiao;ZHAO Feng;MA Yin-ling;WU Xian;CAO De-ying(Department of Pharmaceutics,School of Pharmacy,Hebei Medical University,Shijiazhuang 050017,China;Department of Pharmacy,Hebei General Hospital,Shijiazhuang 050051,China)

机构地区：[1]河北医科大学药学院药剂学教研室,石家庄050017 [2]河北省人民医院药学部,石家庄050051

出　　处：《中国药学杂志》2022年第10期779-783,共5页Chinese Pharmaceutical Journal

基　　金：国家自然科学基金项目资助(81773666);河北省自然科学基金项目资助(H2020307043);河北省卫生厅医学科学研究重点课题资助(20170472);河北医科大学大学生创新性实验计划项目资助(USIP2020050、USIP2020143)。

摘　　要：乳腺癌仍是威胁女性健康的主要疾病,近年来,有关乳腺癌治疗的经皮给药系统也取得了一定的进展。利用微乳、脂质体、水凝胶和微针等新的经皮给药策略,不仅可以使药物治疗乳腺癌的临床效果更加显著,而且无痛、自给药的治疗方法也使患者更易接受。故本文将对经皮给药治疗乳腺癌的给药系统的特点进行总结,并对未来经皮治疗乳腺癌进行展望。Breast cancer is still a major disease threatening women′s health.In recent years,some progress has been made in transdermal drug delivery system for breast cancer treatment.New transdermal drug delivery strategies,including microemulsion,liposomes,hydrogels and microneedles,not only make the clinical efficacy of drugs for breast cancer more significant,but also make the painless,self⁃contained treatment more acceptable to patients.Therefore,this paper summarizes the characteristics of percutaneous drug delivery system for breast cancer,and could make an outlook for the future of percutaneous drug delivery for breast cancer.

关 键 词：经皮给药系统 局部给药 乳腺癌 纳米制剂 

分 类 号：R944[医药卫生—药剂学]